Abirami Sivapiragasam
Overview
Explore the profile of Abirami Sivapiragasam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
91
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ashok Kumar P, Sampat P, Sandhu M, Suresh Kumar V, Smith A, Paulraj S, et al.
Breast Cancer Res Treat
. 2025 Jan;
PMID: 39827229
Background: Cryotherapy with taxane infusion is a noninvasive strategy for preventing peripheral neuropathy (PN), but the efficacy of this approach has not been proven. Methods: A systematic search was conducted,...
2.
Ashok Kumar P, Wang D, Huang D, Sivapiragasam A
JCO Precis Oncol
. 2024 Apr;
8:e2300390.
PMID: 38564683
Purpose: Results from the TAILORx trial revealed that the use of adjuvant chemotherapy along with endocrine therapy had no survival advantage in patients with estrogen receptor (ER)-positive, human epidermal growth...
3.
Ashok Kumar P, Sivapiragasam A, Wang D, Huang D, Gentile T
Clin Lymphoma Myeloma Leuk
. 2023 Sep;
23(12):897-904.
PMID: 37690902
Background: Gamma delta T cells gives rise to a rare malignancy called Primary cutaneous Gamma-Delta T cell lymphoma (PCGDTCL). Methods: From the National Cancer Database (NCDB), 110 (0.015%) patients with...
4.
Zerdan M, Ashok Kumar P, Haroun E, Srivastava N, Ross J, Sivapiragasam A
Oncotarget
. 2023 Aug;
14:747.
PMID: 37552224
No abstract available.
5.
Ashok Kumar P, Serinelli S, Zaccarini D, Huang R, Danziger N, Janovitz T, et al.
Front Oncol
. 2023 Jul;
13:1169586.
PMID: 37404765
Introduction: KRAS mutation is a common occurrence in Pancreatic Ductal Adenocarcinoma (PDA) and is a driver mutation for disease development and progression. KRAS wild-type PDA may constitute a distinct molecular...
6.
Sandhu M, Ashok Kumar P, Deck J, Zerdan M, Lacombe M, Sivapiragasam A
J Investig Med High Impact Case Rep
. 2023 Apr;
11:23247096231168114.
PMID: 37096743
Radiation recall dermatitis is an inflammatory reaction of the skin that may infrequently occur in areas of the skin that have been previously treated with radiation therapy. This is thought...
7.
Zerdan M, Ashok Kumar P, Haroun E, Srivastava N, Ross J, Sivapiragasam A
Oncotarget
. 2023 Mar;
14:178-187.
PMID: 36913304
Introduction: Homozygous deletion of upregulates synthesis of purine (DNSP) and increases the proliferation of neoplastic cells. This increases the sensitivity of breast cancer cells to DNSP inhibitors such as methotrexate,...
8.
Zerdan M, Ashok Kumar P, Zaccarini D, Ross J, Huang R, Sivapiragasam A
Biomedicines
. 2023 Feb;
11(2).
PMID: 36831055
Introduction: Salivary gland carcinomas (SGC) are histologically diverse cancers and next-generation sequencing (NGS) to identify key molecular targets is an important aspect in the management of advanced cases. Methods: DNA...
9.
Akhtar K, Sravanthi M, DAngelo J, Sivapiragasam A
J Investig Med High Impact Case Rep
. 2022 Aug;
10:23247096221121408.
PMID: 36017984
Cemiplimab, a monoclonal antibody directed against programmed death receptor 1 (PD-1), has shown promising results in cutaneous squamous cell carcinoma (cSCC). In a nonrandomized trial where cemiplimab 3 mg/kg was...
10.
Ashok Kumar P, Wang D, Huang D, Paulraj S, Sivapiragasam A
Cureus
. 2022 Aug;
14(7):e27109.
PMID: 36000118
Background: Lacrimal gland tumors are rare with data limited to very few large studies. Contemporary strategies like orbit sparing surgeries and neoadjuvant intraarterial chemotherapy remain controversial. Methods: This is a...